CCND1 amplification and relapse-free survival.

RFS for patients with CCND1 gene amplification or not, showing benefit from tamoxifen in both groups. Kaplan-Meier curves for RFS, tamoxifen vs. placebo in patients with CCDN1 gene non-amplified (“low CCND1”) (A) and amplified (“high CCND1”) (B) tumors. Adjusted HRs are included for the comparison of tamoxifen vs. placebo in each group.

Categories

License

CC BY 4.0